Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1546-1551

  Salvatore, C M ^a   Techasaensiri, C ^a   Tagliabue, C ^c   Katz, K ^a   Leos, N ^b   Gomez, A M ^b   McCracken, G H ^a   Hardy, R D ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE REDUCTION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; HISTOPATHOLOGY; IMMUNOLOGY; IN VITRO STUDY; INFLAMMATION; LUNG LAVAGE; MICROBIOLOGY; MOUSE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MICE; MICE, INBRED BALB C; MINOCYCLINE; PNEUMONIA, MYCOPLASMA;

EID: 65649118628     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00979-08     Document Type: Article

References (42)

1. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and J. C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric com-munity-acquired pneumonia: comparative efficacy and safety of clarithromy-cin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14:471-477.
2. Canton, R., S. Unal, and D. J. Farrell. 2007. Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1-5 (1999-2004). Int. J. Antimicrob. Agents 30:546-550. (Pubitemid 350051778)
3. Cassell, G. H., and B. C. Cole. 1981. Mycoplasmas as agents of human disease. N. Engl. J. Med. 304:80-89. (Pubitemid 11170312)
4. Cimolai, N., G. P. Taylor, D. Mah, and B. J. Morrison. 1992. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol. Immunol. 36:465-478.
5. Denny, F. W., W. A. Clyde, Jr., and W. P. Glezen. 1971. Mycoplasma pneu-moniae disease: clinical spectrum, pathophysiology, epidemiology, and con-trol. J. Infect. Dis. 123:74-92.
6. Doern, G. V., and S. D. Brown. 2004. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J. Infect. 48:56-65. (Pubitemid 38072202)
7. Esposito, S., F. Blasi, C. Arosio, L. Fioravanti, L. Fagetti, R. Droghetti, P. Tarsia, L. Allegra, and N. Principi. 2000. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheez-ing. Eur. Respir. J. 16:1142-1146. (Pubitemid 32148131)
8. Esposito, S., S. Bosis, N. Faelli, E. Begliatti, R. Droghetti, E. Tremolati, A. Porta, F. Blasi, and N. Principi. 2005. Role of atypical bacteria and azithro-mycin therapy for children with recurrent respiratory tract infections. Pedi-atr. Infect. Dis. J. 24:438-444. (Pubitemid 40664240)
9. Fonseca-Aten, M., A. M. Rios, A. Mejias, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken, Jr., and R. D. Hardy. 2005. Mycoplasma pneu-moniae induces host-dependent pulmonary inflammation and airway ob-struction in mice. Am. J. Respir. Cell MoI. Biol. 32:201-210. (Pubitemid 40387646)
10. Fonseca-Aten, M., C. M. Salvátore, A. Mejias, A. M. Rios, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken, Jr., and R. D. Hardy. 2005. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhib-itor, for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 49:4128-4136. (Pubitemid 41400955)
11. Gendrel, D. 1997. Antibiotic treatment of Mycoplasma pneumoniae infections. Pediatr. Pulmonol. Suppl. 16:46-47. (Pubitemid 28070743)
12. Gendrel, D., J. Raymond, F. Moulin, J. L. Iniguez, S. Ravilly, F. Habib, P. Lebon, and G. Kalifa. 1997. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur. J. Clin. Microbiol. Infect. Dis. 16:388-391. (Pubitemid 27271830)
13. Hardy, R. D., H. S. Jafri, K. Olsen, J. Hatfield, J. Iglehart, B. B. Rogers, P. Patel, G. Cassell, G. H. McCracken, and O. Ramilo. 2002. Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease. Infect. Immun. 70:649-654. (Pubitemid 34083823)
14. Hardy, R. D., H. S. Jafri, K. Olsen, M. Wordemann, J. Hatfield, B. B. Rogers, P. Patel, L. Duffy, G. Cassell, G. H. McCracken, and O. Ramilo. 2001. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a micro-biologic, histologic, immunologic, and respiratory Plethysmographie profile. Infect. Immun. 69:3869-3876. (Pubitemid 32493307)
15. Hardy, R D., A. M. Rios, S. Chavez-Bueno, H. S. Jafri, J. Hatfield, B. B. Rogers, G. H. McCracken, and O. Ramilo. 2003. Antimicrobial and immu-nologic activities of clarithromycin in a murine model oí Mycoplasma pneu-moniae-ináuced pneumonia. Antimicrob. Agents Chemother. 47:1614-1620. (Pubitemid 36548545)
16. Hoellman, D. B., G. A. Panknch, M. R Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneu-mococci. Antimicrob. Agents Chemother. 44:1085-1088. (Pubitemid 30165298)
17. Johnson, A. P., C. L. Sheppard, S. J. Harnett, A. Birtles, T. G. Harrison, N. P. Brenwald, M. J. Gill, R. A. Walker, D. M. Livermore, and R. C. George. 2003. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneu-moniae in England. J. Antimicrob. Chemother. 52:953-960. (Pubitemid 38008415)
18. Jones, R. N. 2001. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119:397S-404S. (Pubitemid 32163809)
19. Kannan, T. R., and J. B. Baseman. 2006. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determi-nant among bacterial pathogens. Proc. Natl. Acad. Sei. USA 103:6724-6729.
20. Kenny, G. E., and F. D. Cartwright. 2001. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfo-pristin, dirithromycin, evernimicin, gatifioxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibili-ties to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45:2604-2608. (Pubitemid 32801917)
21. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. 37:1726-1727. (Pubitemid 23226396)
22. Kraft, M. 2000. The role of bacterial infections in asthma. Clin. Chest Med. 21:301-313. (Pubitemid 30434641)
23. Kraft, M., G. H. Cassell, J. E. Henson, H. Watson, J. Williamson, B. P. Marmion, C. A. Gaydos, and R. J. Martin. 1998. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am. J. Respir. Crit. Care Med. 158:998-1001. (Pubitemid 28449473)
24. Kraft, M., and Q. Hamid. 2006. Mycoplasma in severe asthma. J. Allergy Clin. Immunol. 117:1197-1198.
25. Marc, E., M. Chaussain, F. Moulin, J. L. Iniguez, G. Kalifa, J. Raymond, and D. Gendrel. 2000. Reduced lung diffusion capacity after Mycoplasma pneumoniae pneumonia. Pediatr. Infect. Dis. J. 19:706-710. (Pubitemid 30644038)
26. McCracken, G. H., Jr. 1986. Current status of antibiotic treatment for My-coplasma pneumoniae infections. Pediatr. Infect. Dis. 5:167-171.
27. Michelow, I. C, K. Olsen, J. Lozano, N. K Rollins, L. B. Duffy, T. Ziegler, J. Kauppila, M. Leinonen, and G. H. McCracken, Jr. 2004. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113:701-707. (Pubitemid 38437371)
28. Nilsson, A. C, P. Björkman, and K Persson. 2008. Polymerase chain reac-tion is superior to serology for the diagnosis of acute Mycoplasma pneu-moniae infection and reveals a high rate of persistent infection. BMC Microbiol. 8:93.
29. Nord, C. E., A. Lindmark, and I. Persson. 1993. In vitro activity of DMG-Mino and DMG-DM. Dot, two new glycylcyclines, against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 12:784-786. (Pubitemid 23326563)
30. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Che-mother. 38:1658-1660. (Pubitemid 24203587)
31. Rios A. M., M. Fonseca-Aten, A. Mejias, S. Chavez-Bueno, K Katz, A. M. Gomez, G. H. McCracken, Jr., O. Ramilo, and R. D. Hardy. 2005. Microbi-ologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 49:3970-3973. (Pubitemid 41233063)
32. Rios, A. M., A. Mejias, S. Chavez-Bueno, M. Fonseca-Aten, K. Katz, J. Hatfield, A. M. Gomez, H. S. Jafri, G. H. McCracken, Jr., O. Ramilo, and R. D. Hardy. 2004. Impact of cethromycin (ABT-773) therapy on microbi-ological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob. Agents Chemother. 48:2897-2904. (Pubitemid 38989153)
33. Rubinstein, E., and D. Vaughan. 2005. Tigecycline: a novel glycylcycline. Drugs 65:1317-1336. (Pubitemid 41043889)
34. Salvátore, C. M., M. Fonseca-Aten, K. Katz-Gaynor, A. M. Gomez, and R. D. Hardy. 2008. Intranasal interleukin-12 therapy inhibits Mycoplasma pneu-moniae clearance and sustains airway obstruction in murine pneumonia. Infect. Immun. 76:732-738.
35. Salvátore, C. M., M. Fonseca-Aten, K Katz-Gaynor, A. M. Gomez, A. Me-jias, C. Somers, S. Chavez-Bueno, G. H. McCracken, and R. D. Hardy. 2007. Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmo-nary inflammation. Infect. Immun. 75:236-242. (Pubitemid 46047898)
36. Smith, C. B., W. T. Friedewald, and R. M. Chanock. 1967. Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy. N. Engl. J. Med. 276:1172-1175.
37. Sum, P. E., V. J. Lee, R. T. Testa, J. J. Hlávka, G. A. Ellestad, J. D. Bloom, Y. Gluzman, and F. P. Tally. 1994. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J. Med. Chem. 37:184-188. (Pubitemid 24058829)
38. Tagliabue, C, C. M. Salvátore, C. Techasaensiri, A. Mejias, J. P. Torres, K. Katz, A. M. Gomez, S. Esposito, N. Principi, and R. D. Hardy. 2008. The impact of steroids given with macrolide therapy on experimental Myco-plasma pneumoniae respiratory infection. J. Infect. Dis. 198:1180-1188.
39. Testa, R. T., P. J. Petersen, N. V. Jacobus, P. E. Sum, V. J. Lee, and F. P. Tally. 1993. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. 37:2270-2277. (Pubitemid 23324443)
40. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two gly-cylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949. (Pubitemid 30165274)
41. Wallace, R. J., Jr., B. A. Brown-Elliott, C. J. Crist, L. Mann, and R. W. Wilson. 2002. Comparison of the in vitro activity of the glycylcycline tigecy-cline (formerly GAR-936) with those of tetracycline, minocycline, and doxy-cycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46:3164-3167.
42. Wubbel, L., L. Muniz, A. Ahmed, M. Trujillo, C. Carubelli, C. McCoig, T. Abramo, M. Leinonen, and G. H. McCracken, Jr. 1999. Etiology and treat-ment of community-acquired pneumonia in ambulatory children. Pediatr. Infect. Dis. J. 18:98-104. (Pubitemid 29101880)